SAN DIEGO, California — October 10, 2025 — Leads & Copy — Cidara Therapeutics, Inc. (Nasdaq: CDTX) will present late-breaking data on its antiviral candidate CD388 at the European Scientific Working Group on Influenza (ESWI)’s 10th Influenza Conference, taking place October 20-23, 2025, in Valencia, Spain.
The presentation, titled “Translational efficacy of CD388, a novel Drug Fc-Conjugate (DFC), in mouse influenza infection models: application to prevention efficacy in the recently completed Ph2b NAVIGATE clinical study,” will be delivered by Voon Ong, Ph.D., during the “Late Breakers: Novel and Outstanding Discoveries” session on Thursday, October 23, 2025, from 2:00-3:30 pm CET.
Cidara utilizes its Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics. CD388, the company’s lead DFC candidate, aims for universal prevention of seasonal and pandemic influenza with a single dose, directly inhibiting viral proliferation. The FDA granted CD388 Fast Track Designation in June 2023. Cidara announced positive top-line results from its Phase 2b NAVIGATE trial in June 2025 and initiated its Phase 3 ANCHOR trial in September 2025. Cidara is headquartered in San Diego, California.
Investor Contact: Brian Ritchie, LifeSci Advisors, (212) 915-2578, britchie@lifesciadvisors.com; Media Contact: Michael Fitzhugh, LifeSci Communications, (628) 234-3889, mfitzhugh@lifescicomms.com
Source: Cidara Therapeutics
